Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06044311 · ClinicalTrials.gov registry record · Phase 2
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma
A Phase 2 study of Adenocarcinoma Esophagus and Locally Advanced Adenocarcinoma, sponsored by Sakti Chakrabarti.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06044311: Recruiting Phase 2 study of Adenocarcinoma Esophagus and Locally Advanced Adenocarcinoma, sponsored by Sakti Chakrabarti.
NCT06044311 is a Phase 2 study of Adenocarcinoma Esophagus and Locally Advanced Adenocarcinoma that is actively recruiting participants, run by Sakti Chakrabarti. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06044311, a Phase 2 study of Adenocarcinoma Esophagus and Locally Advanced Adenocarcinoma, is actively recruiting participants, sponsored by Sakti Chakrabarti.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This interventional clinical trial aims to find ways of improving treatments for individuals with esophageal cancer. Laboratory-based studies show that using medicines that affect a protein called TGF-beta (TGFβ) can kill esophageal cancer cells in individuals who have localized esophageal adenocarcinoma and are being considered for standard-of-care chemoradiation prior to surgery. Participants of this study will take a pill called vactosertib for two weeks before starting standard of care chemoradiation. At the end of the two weeks of taking vactosertib, participants will have a Positron Emission Tomography Computer Assisted Tomography (PET CT) scan and undergo an endoscopy with a biopsy to determine if the vactosertib is working. After chemoradiation, participants will take vactosertib again for four weeks and then be considered for surgery.
Conditions Studied
Interventions
- DRUG Standard of Care Chemotherapy
- DRUG Vactosertib
- RADIATION Concurrent Radiation
Study Locations (1)
Ohio
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
What NCT06044311 shows while recruiting
NCT06044311 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 4 conditions, with Adenocarcinoma Esophagus appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care Chemotherapy is the first listed.
NCT06044311 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06044311 about?
NCT06044311 is a clinical study titled "Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma". This interventional clinical trial aims to find ways of improving treatments for individuals with esophageal cancer. Laboratory-based studies show that using medicines that affect a protein called TGF-beta (TGFβ) can kill esophageal cancer cells in individuals who have localized esophageal adenocarc...
What is the current status of trial NCT06044311?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-09-30. Estimated completion is 2027-06-01.
What conditions does trial NCT06044311 study?
This clinical trial studies the following conditions: Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction.
What interventions are being tested in trial NCT06044311?
The interventions under investigation include: Standard of Care Chemotherapy (DRUG), Vactosertib (DRUG), Concurrent Radiation (RADIATION).
Who is sponsoring clinical trial NCT06044311?
This trial is sponsored by Sakti Chakrabarti, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06044311 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma Esophagus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06044311's enrollment target sits among peer trials
25 1719th of 2000 higher than 246 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI